We have located links that may give you full text access.
Evaluation of Serum Paired MicroRNA Ratios for Differential Diagnosis of Non-Small Cell Lung Cancer and Benign Pulmonary Diseases.
Molecular Diagnosis & Therapy 2018 June 20
BACKGROUND AND OBJECTIVE: To clarify whether there are different expressions between lung cancer and benign pulmonary diseases, we studied seven microRNAs (miRNAs) in serum from patients with non-small cell lung cancer (NSCLC), benign pulmonary nodules and four pulmonary inflammation diseases.
METHODS: We detected the expression of miRNAs using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR).
RESULTS: We found that five miRNA ratios-miR-15b-5p/miR-146b-3p, miR-20a-5p/miR-146b-3p, miR-19a-3p/miR-146b-3p, miR-92a-3p/miR-146b-3p, and miR-16-5p/miR-146b-3p-show higher expression in the NSCLC group than the benign pulmonary nodule group, and 13 ratios of miRNAs were significantly upregulated in the NSCLC group compared with the pulmonary inflammation diseases group. Receiver operating characteristic (ROC) curve analysis was performed. For NSCLC and benign pulmonary nodules, the sensitivity and specificity were 0.70 and 0.90, respectively. For NSCLC and pulmonary inflammation diseases, the sensitivity and specificity were 0.81 and 0.71, respectively.
CONCLUSION: The ratios of miRNAs can be used as potential non-invasive biomarkers for diagnosis of early-stage NSCLC and benign pulmonary diseases.
METHODS: We detected the expression of miRNAs using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR).
RESULTS: We found that five miRNA ratios-miR-15b-5p/miR-146b-3p, miR-20a-5p/miR-146b-3p, miR-19a-3p/miR-146b-3p, miR-92a-3p/miR-146b-3p, and miR-16-5p/miR-146b-3p-show higher expression in the NSCLC group than the benign pulmonary nodule group, and 13 ratios of miRNAs were significantly upregulated in the NSCLC group compared with the pulmonary inflammation diseases group. Receiver operating characteristic (ROC) curve analysis was performed. For NSCLC and benign pulmonary nodules, the sensitivity and specificity were 0.70 and 0.90, respectively. For NSCLC and pulmonary inflammation diseases, the sensitivity and specificity were 0.81 and 0.71, respectively.
CONCLUSION: The ratios of miRNAs can be used as potential non-invasive biomarkers for diagnosis of early-stage NSCLC and benign pulmonary diseases.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app